Since his appointment as CEO of Synaffix in 2011, Peter has been responsible for implementing a strategic shift at the Company, refocusing exclusively on antibody-drug conjugates (ADCs). In a short timeframe, this shift has seen Synaffix transition from an academic spin-out into a leading biotech in the field of ADCs. This new strategy has been validated by a string of commercial licensing agreements with prominent ADC developers across the US, Europe and China. Prior to joining Synaffix, Peter spent over 10 years in the chemical industry, holding various executive positions at CPS Color (now Chromaflo/Corob). He received his MSc degree in Chemical Engineering from Eindhoven University of Technology, an Executive MBA degree from Kellogg School of Management and a Master of Business Law (MBL) degree from Sydney University.
Floris graduated in organic chemistry from Leiden University (1996, cum laude) in the Netherlands. After a post-doctoral stay at the Scripps Research Institute (San Diego), he held various professorships, including a special professorship at Wageningen University in the Netherlands (2015-2020; focused on click chemistry and protein conjugation technologies). Floris co-founded Synaffix in 2010 and became the full-time Chief Scientific Officer (CSO) in 2014. He has been the driving force behind the invention of the proprietary technologies that now form the basis of Synaffix’s best-in-class antibody-drug conjugate (ADC) technology platform, used to generate targeted cancer therapeutics. Floris has (co)authored >150 peer-reviewed publications and is (co)inventor of 25 patent applications.
Sander van Berkel, Ph.D., has served as VP, R&D Operations of Synaffix since January 2020. Prior to founding Synaffix, Dr. van Berkel performed postdoctoral research on novel conjugation methodologies for non-invasive cancer imaging at University of Oxford. Preceding Oxford, he worked at the Leibniz-Institute of Plant Biochemistry in Halle, Germany, as postdoctoral researcher focusing on the synthesis of anti-tumor agent epothilone B and its derivatives. He holds a PhD and an MSc in Organic Chemistry from the Radboud University Nijmegen, the Netherlands. He is an inventor on multiple patents and has been an author of 40 peer-reviewed publications and reviews.
Peter has collected broad experience across all aspects of CMC development ranging from preclinical to commercial-stage assets. Notably, Peter previously served as Director CMC at Janssen Vaccines and more recently as Director of CMC and Head of Operations at Staten Biotechnology. Separately, Peter has supported multiple biotechs in a strategic CMC consultant capacity related to process and analytical development, as well as regulatory and compliance strategies and filings. His experience encompasses many different drug types, such as antibodies, vaccines, and live bacteria.
Prior to joining Synaffix in 2014, Anthony served as the Associate Director of Business Development at Allozyne, a Seattle-based biotech, where he was focused on partnering efforts around pipeline programs and antibody-drug conjugate technology leading up to an acquisition by MedImmune. Previously, he studied in the laboratory of Dr. Irv Weissman at the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Anthony is a published co-author in Nature and PNAS and holds a BSc in Biotechnology from Seattle Pacific University.
Prior to joining Synaffix in 2023, Harold held several FD/CFO positions at international companies, within different types of branches varying from ICT, Recruitment and FMCG.
His career has had a strong focus on process improvements, cost controlling, business strategy and he has lead several ERP implementation projects. Previously, he studied Economics and Controlling at Maastricht University.
Bring your own and/or choose from the following categories.
Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.
Early preclinical data available on request.
NK cell recruitment
NK cell recruitment
Forming an integral part of every toxSYN®
linker-payload, HydraSpace® bears a negative charge at physiological pH and improves:
GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).
| toxSYN® Linker-Payload |
Mode-of-Action | Payload (Active Catabolite) |
|---|---|---|
| 1. SYNtecan E™* | Topoisomerase 1 inhibitor | Camptothecin-based |
| 2. SYNeamicin D™* | DNA damaging agent |
Calicheamicin-based |
| 3. SYNeamicin G™* | ||
| 4. SYN-PNU™* | Nemorubicin-based | |
| 5. SYNstatin E™ | Microtubule inhibitors |
Auristatin-based |
| 6. SYNstatin F™ | ||
| 7. SYNtansine™ | Maytansine-based |
* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace®
** N-6-aminohexanoyl-maytansine (Ahx-maytansine)
